A

Alumis

Develops precision therapies for immune diseases

Senior/Executive Medical Director - Clinical Development, New Indications

Clinical Research OperationsConfirmed live in the last 24 hours
Full-timeSouth San Francisco, CA, USA$300k - $400k /yr

About the Job

Requirements

  • An MD is required, along with neurology experience; board certification or fellowship training in Neurology is highly desired.
  • At least 10 years of pharmaceutical or biotechnology industry experience in clinical development, with significant focus on neurology; immunology or autoimmune disease experience is a plus.
  • Demonstrated experience leading Phase 1 and Phase 2 clinical studies from design through data readout.
  • A track record of successful regulatory interactions with the FDA and EMA, and experience preparing IND/CTA submissions.
  • Deep understanding of early clinical development, including dose-finding strategies, biomarker integration, and adaptive trial designs.
  • Strong scientific acumen and the ability to critically evaluate preclinical and clinical data to inform development strategy.
  • Experience with JAK/TYK2 inhibitors or related immunomodulatory mechanisms is preferred.
  • Experience with indication expansion or lifecycle management for neurology or immunology assets is preferred.
  • Prior experience at a small or mid-sized biotechnology company and comfort operating in a fast-paced, resource-conscious environment are preferred.
  • Established relationships with key opinion leaders in neurology are preferred; relationships in rheumatology, dermatology, or other inflammatory disease areas are also valued.
  • Experience across multiple therapeutic indications, including neurological diseases such as neurodegenerative diseases or movement disorders, and/or inflammatory conditions such as psoriasis, psoriatic arthritis, lupus, or atopic dermatitis, is preferred.
  • Familiarity with regulatory pathways for expedited development, including Breakthrough Therapy and Fast Track, is preferred.

Responsibilities

  • Lead the design, planning, and execution of Phase 1 and Phase 2 clinical studies for A-005 in neurology, including neurodegenerative diseases and movement disorders, and for additional pipeline molecules in inflammatory and immunologic indications.
  • Develop and refine clinical development plans, including study synopses, protocols, and integrated development strategies for new indications.
  • Provide clinical and scientific leadership to cross-functional study teams, ensuring alignment on program goals, timelines, and deliverables.
  • Collaborate with Translational Medicine and Research teams to evaluate and prioritize new indication opportunities based on scientific rationale, competitive landscape, and unmet medical need.
  • Serve as the Medical Monitor for assigned Phase 1 and Phase 2 studies, ensuring patient safety and scientific integrity.
  • Oversee medical aspects of study conduct, including safety surveillance, protocol amendments, and data review.
  • Partner with Clinical Operations, Biostatistics, and Regulatory Affairs to ensure efficient study execution and high-quality data generation.
  • Lead interactions with Data Safety Monitoring Boards and provide medical input for safety analyses.
  • Contribute to regulatory strategy and serve as a clinical representative in interactions with the FDA and international regulatory authorities, including EMA and PMDA.
  • Prepare and review clinical sections of regulatory submissions, including IND amendments, briefing documents, and meeting packages.
  • Represent Alumis at scientific conferences and advisory boards, and engage with key opinion leaders to advance clinical programs and gather external insights.
  • Build and maintain relationships with investigators, academic collaborators, and the broader medical community.
  • Work closely with Translational Sciences, Biomarker, and Pharmacology teams to integrate biomarker strategies into clinical study designs.
  • Collaborate with Commercial and Medical Affairs teams on disease landscape assessments and indication prioritization.
  • Provide clinical expertise to support business development activities, including evaluation of potential partnerships or in-licensing opportunities.
  • Mentor and develop junior medical staff, fostering a culture of scientific excellence and collaboration.
  • Contribute to building Alumis’s clinical development capabilities as the organization grows.
  • Travel approximately 20–30% for investigator meetings, scientific conferences, regulatory interactions, and site visits.

Desired Qualifications

  • Additional experience in inflammatory disease areas, such as rheumatology or dermatology, is a plus.
  • Experience with JAK/TYK2 inhibitors or related immunomodulatory mechanisms is preferred.
  • Experience with indication expansion or lifecycle management for neurology or immunology assets is preferred.
  • Prior experience at a small or mid-sized biotechnology company and comfort operating in a fast-paced, resource-conscious environment are preferred.
  • Established relationships with key opinion leaders in neurology are preferred; relationships in rheumatology, dermatology, or other inflammatory disease areas are also valued.
  • Experience across multiple therapeutic indications, including neurological diseases such as neurodegenerative diseases or movement disorders, and/or inflammatory conditions such as psoriasis, psoriatic arthritis, lupus, or atopic dermatitis, is preferred.
  • Familiarity with regulatory pathways for expedited development, including Breakthrough Therapy and Fast Track, is preferred.

About the Company

Alumis

Develops precision therapies for immune diseases

Alumis develops precision therapies for immune-mediated diseases in the biotech and pharmaceutical space. Its products are designed by using genetic and disease biology to select targets and patient groups, delivering targeted therapies and measuring success through specific endpoints. The company differentiates itself by tying target selection and trial design to detailed immunologic and genetic insights to match the right medicine with the right patients. Its goal is to improve clinical outcomes by bringing precision therapies to market and forming strategic partnerships or licensing deals to support development and commercialization.

Company size
201-500
Company stage
IPO
Headquarters
South San Francisco, CA
Founded
2021

Recently Posted Jobs

Explore more opportunities at Alumis

See more jobs